ArticleFrontiers in surgery2025
Impact of dexmedetomidine on postoperative cognitive dysfunction and inflammatory response in older adult female patients undergoing laparoscopic cholecystectomy.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of the present study was to identify the minimum effective dose of dexmedetomidine (Dex) that could be safely and effectively promoted for clinical application. A rigorous comparison between multiple Dex dosage groups and the control group was conducted. Methods: Based on the inclusion criteria, 165 elderly patients undergoing LC in our hospital were randomly divided into four groups: Group C (the control group, 32 patients), group D1 (low-dose Dex, 41 patients), group D2 (medium-dose Dex, 49 patients), and group D3 (high-dose Dex, 43 patients). The effects of different doses of Dex on postoperative cognitive impairment, pain scores, and inflammatory markers were subsequently studied in the selected patients. Results: Patients who received the medium dosage of Dex experienced significantly lower incidences of postoperative agitation and tachycardia compared with the control group, and all doses of Dex reduced the incidence of Postoperative cognitive dysfunction (POCD). It was highlighted the efficacy of medium and high doses of Dex in achieving superior analgesia (as evidenced by lower VAS scores) at different postoperative time points. Concordantly, it was also revealed a similar pattern in postoperative recovery quality. After comparing the low-dose, medium-dose, and high-dose groups with the control group, we found that only the medium-dose group significantly decreased the expression levels of IL-1β and TNF-α both on the first day and second day postoperatively, while the expression levels of IL-10 increased. Discussion and Conclusion: In conclusion, compared with normal saline, a 0.6 μg/kg/h maintenance dose of Dex is the optimal dosing regimen for improving postoperative cognitive function and had a better anti-inflammation effect in elderly female patients following LC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.